PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 17, 2026Journal of Clinical Medicine0 citationsOpen Access

Early Postoperative Dupilumab After Revision Endoscopic Sinus Surgery for CRSwNP: A Real-World Single-Centre Study

View Full Paper
JGJuan David Gutiérrez-PossoAMAitor Zabala-Lopez de Maturana

Key Points

  • The study aims to evaluate the impact of early postoperative dupilumab initiation on clinical outcomes after revision endoscopic sinus surgery for severe chronic rhinosinusitis with nasal polyps.
  • Retrospective observational study design
  • Included adults with severe chronic rhinosinusitis treated with dupilumab
  • Patients had undergone at least two previous endoscopic sinus surgeries
  • Dupilumab was initiated within 30 days post-surgery
  • Outcomes assessed included nasal polyp score, sinonasal outcome test, nasal congestion, and olfactory VAS scores
  • Significant improvement in nasal polyp score from 4.7 to 0.4 (p=0.0019)
  • SNOT-22 score improved from 61.9 to 26.5 (p=0.0019)
  • Nasal congestion and olfactory scores also showed significant improvement
  • 70% of patients achieved an excellent multidimensional response, 30% a moderate response
  • No systemic corticosteroids or revision surgeries required during follow-up

Abstract

Background/Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease frequently associated with recurrence after endoscopic sinus surgery (ESS). Although biologic therapies such as dupilumab have demonstrated efficacy in severe CRSwNP, the optimal timing of treatment initiation in relation to surgery remains unclear. This study aimed to evaluate the clinical outcomes of early postoperative initiation of dupilumab after revision ESS using a multidimensional assessment of disease control. Methods: This retrospective observational study included adult patients with severe CRSwNP treated with dupilumab at a tertiary referral centre. All patients had undergone at least two previous ESS procedures and initiated dupilumab within 30 days following revision surgery. Clinical outcomes were assessed at baseline and after 12 months, including Nasal Polyp Score (NPS), Sinonasal Outcome Test-22 (SNOT-22), nasal congestion and olfactory visual analogue scale (VAS) scores, and asthma control in patients with comorbid asthma. Treatment response was evaluated using a multidomain assessment. Results: Ten patients were included. After 12 months, significant improvements were observed in NPS (from 4.7 ± 2.3 to 0.4 ± 1.0; p = 0.0019) and SNOT-22 (from 61.9 ± 17.3 to 26.5 ± 14.7; p = 0.0019). Nasal congestion and olfactory VAS scores also improved significantly. Most patients (70%) achieved an excellent multidimensional response, while 30% showed a moderate response. No patients required systemic corticosteroids or revision surgery during follow-up. Conclusions: Early postoperative initiation of dupilumab after revision ESS was associated with improvements in endoscopic findings, symptom severity, and quality of life. These findings suggest that the early postoperative period may represent a therapeutic window in selected patients with severe recurrent CRSwNP. However, results should be interpreted with caution and considered hypothesis-generating.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gutiérrez-Posso et al. (2026) studied this question.

synapsesocial.com/papers/69e1d0165cdc762e9d8592e4https://doi.org/10.3390/jcm15083015
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Does Prior Sinus Surgery Influence Dupilumab Treatment Response in CRSwNP?2026
  2. 2Dupilumab: a delayed response in asthmatic and atopic patients treated for chronic rhinosinusitis with nasal polyps2024 · 2 citations
  3. 3Optimal Timing of Dupilumab Application in CRSwNP: Impact of “Neoadjuvant Therapy” on Surgical Outcomes at 1 Year2025
  4. 4Prospective Real‐World Outcomes of Endoscopic Sinus Surgery and Dupilumab in Severe Chronic Rhinosinusitis With Nasal Polyps2026
  5. 5Dupilumab improved objective and patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and complete nasal obstruction2024 · 2 citations